Understanding liver macrophages to predict fibrosis risk in chronic liver disease

ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE

['FUNDING_R01'] · UNIVERSITY OF TEXAS MED BR GALVESTON · NIH-11083599

This study is looking at how certain immune cells in the liver can help doctors understand the risk of liver damage in people with chronic liver diseases, like fatty liver disease or alcohol-related liver issues, so they can create personalized treatments to prevent serious problems.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF TEXAS MED BR GALVESTON (nih funded)
Locations1 site (GALVESTON, UNITED STATES)
Trial IDNIH-11083599 on ClinicalTrials.gov

What this research studies

This research investigates how specific immune cells in the liver, known as macrophages, can help predict the risk of fibrosis in patients with various chronic liver diseases such as non-alcoholic fatty liver disease and alcohol-associated liver disease. By analyzing liver biopsies using advanced imaging and genetic profiling techniques, the study aims to identify patterns that could indicate how likely a patient is to develop severe liver damage. This personalized approach could lead to tailored therapies that address individual patient needs before serious complications arise.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with chronic liver diseases such as NASH, alcohol-associated liver disease, chronic hepatitis, or autoimmune hepatitis.

Not a fit: Patients with acute liver conditions or those who do not have chronic liver diseases may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved methods for predicting liver disease progression and more personalized treatment options for patients.

How similar studies have performed: Other research has shown promising results in using immune cell profiles to predict disease outcomes, suggesting that this approach may be effective.

Where this research is happening

GALVESTON, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: alcohol induced hepatic injury, alcohol induced liver disorder, alcohol induced liver injury, alcohol related liver disease, alcohol-associated liver disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.